Vycor Medical, Inc. (OTCQB: VYCO) reported financial results for the year ended December 31, 2025, showing a 17% increase in total revenue to $1,863,400 compared to $1,589,324 in 2024. The company achieved an operating profit of $33,900, a turnaround from an operating loss of $9,145 in the prior year. Non-GAAP operating profit rose to $145,881 from $81,548.
The Vycor Medical division, which manufactures the ViewSite™ Brain Access System (VBAS), generated revenue of $1,796,070, an 18% increase over 2024. Most of the growth came from international markets, a key company strategy, although U.S. sales also continued to grow. Gross profit for the division was $1,498,295, with an 83% margin, down from 89% in 2024 due to higher manufacturing, validation, and shipping costs, as well as a higher international sales mix.
The NovaVision division, which offers vision rehabilitation therapies, reported revenue of $67,330, an 8% decrease from 2024, but maintained a high gross margin of 93%. The company continues to develop NovaVision, and a new clinical study published in 2025 validated NeuroEyeCoach as effective both in-clinic and at home, supporting the trend toward digital health solutions.
During 2025, seven new peer-reviewed studies were published on VBAS, bringing the total to 50 peer-reviewed papers. These studies, originating from the U.S., U.K., Japan, and Mexico, highlighted VBAS's clinical advantages in reducing brain tissue damage, improving patient outcomes, and shortening hospital stays. The growing body of evidence supports the device's adoption in over 350 U.S. hospitals and internationally. For more information on VBAS, visit Vycor VBAS.
Operating expenses on a GAAP basis were $1,527,207, including non-cash depreciation of $63,143 and stock-based compensation of $48,838. Excluding these, non-GAAP cash operating expenses were $1,415,226. The company reported a GAAP net loss available to common stockholders of $396,796, or $0.01 per share, compared to a net loss of $431,570 in 2024. On a non-GAAP basis, net loss was $284,815, or $0.01 per share.
The company's balance sheet and cash flow details were not disclosed, but management emphasized the importance of international expansion and clinical validation. Vycor Medical continues to invest in its patent portfolio, with 49 issued and 8 pending patents for VBAS. The NovaVision suite, including Visual Restoration Therapy (VRT) and NeuroEyeCoach, remains a development-stage asset with significant market potential. For more on NovaVision, visit NovaVision.
Vycor Medical's focus on minimally invasive neurosurgical devices and vision rehabilitation aligns with growing demand for technologies that improve patient outcomes and reduce healthcare costs. The company's progress in achieving operating profitability and expanding its clinical evidence base positions it for continued growth, though challenges remain in scaling NovaVision and managing cost pressures.
